SML2913
Dehydroxylcannabidiol
≥98% (HPLC)
Synonym(s):
2-[(1R,6R)-3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentylphenol, DH-CBD
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| 5 mg | Please contact Customer Service for Availability | PLN 274.00 | |
| 25 mg | Please contact Customer Service for Availability | PLN 1,390.00 |
About This Item
Empirical Formula (Hill Notation):
C21H30O
CAS Number:
Molecular Weight:
298.46
NACRES:
NA.77
UNSPSC Code:
12352200
Quality Level
assay
≥98% (HPLC)
form
oil
optical activity
[α]/D -135 to -120°, c = 0.5 in chloroform-d
color
colorless to light brown
storage temp.
2-8°C
Biochem/physiol Actions
Dehydroxylcannabidiol (DH-CBD) is a synthetic nonpsychoactive cannabinoid that alleviate acute pain and chronic inflammatory pain by targeting α3 GlyRs. Dehydroxylcannabidio restores the function of both hyperekplexic mutant GlyRα1 and GABAAR in the presence of GlyRα1R271Q. Apparently dehydroxylcannabidiol interrupts the protein interaction GlyRα1 and GABAAR.
Synthetic nonpsychoactive cannabinoid that alleviate acute pain and chronic inflammatory pain by targeting α3 GlyRs
1 of 1
This Item | |||
|---|---|---|---|
| form oil | form - | form - | form powder |
| assay ≥98% (HPLC) | assay - | assay - | assay ≥98% (HPLC) |
| Quality Level 100 | Quality Level - | Quality Level - | Quality Level 100 |
| storage temp. 2-8°C | storage temp. - | storage temp. −20°C | storage temp. 2-8°C |
| color colorless to light brown | color - | color - | color white to beige |
| optical activity [α]/D -135 to -120°, c = 0.5 in chloroform-d | optical activity - | optical activity - | optical activity - |
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Repr. 2
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Wei Xiong et al.
The Journal of experimental medicine, 209(6), 1121-1134 (2012-05-16)
Certain types of nonpsychoactive cannabinoids can potentiate glycine receptors (GlyRs), an important target for nociceptive regulation at the spinal level. However, little is known about the potential and mechanism of glycinergic cannabinoids for chronic pain treatment. We report that systemic
Jieping Lu et al.
Neuropharmacology, 133, 224-232 (2018-02-07)
Some cannabinoids have been shown to suppress chronic pain by targeting glycine receptors (GlyRs). Although cannabinoid potentiation of α3 GlyRs is thought to contribute to cannabinoid-induced analgesia, the role of cannabinoid potentiation of α1 GlyRs in cannabinoid suppression of chronic
Guichang Zou et al.
The Journal of biological chemistry, 295(1), 138-145 (2019-11-24)
The functions of the glycine receptor (GlyR) and GABAA receptor (GABAAR) are both impaired in hyperekplexia, a neurological disorder usually caused by GlyR mutations. Although emerging evidence indicates that cannabinoids can directly restore normal GlyR function, whether they affect GABAAR
Global Trade Item Number
| SKU | GTIN |
|---|---|
| SML2913-5MG | 04061841806622 |
| SML2913-25MG | 04061841806615 |